Spruce clears phase II hurdle with lead asset for rare endocrine disorder

26 March 2019
Spruce Biosciences’ tildacerfont (SPR-001) for congenital adrenal hyperplasia (CAH), a rare endocrine disorder, passed muster in a phase II experiment. Proof-of-concept data were disclosed at the Endocrine Society’s annual meeting in New Orleans, ENDO 2019, for the oral corticotrophin-releasing factor type 1 receptor antagonist.

Read More +

 

Neurocrine Shines In Congenital Adrenal Hyperplasia, But Competitor Is Close

13 March 2019
Spruce’s competing drug with same mechanism of action is also in Phase II, with data expected at the end of March.

Read More +

 

Start-Up Spruce Repurposes Lilly Drug For Genetic Adrenal Condition

08 March 2019
Emerging Company Profile: Spruce and Neurocrine are both testing CRF-R1 antagonists for the orphan disease congenital adrenal hyperplasia, with Phase II data coming soon.

Read More +

 

Scientist jumps from academia to startup CEO

05 February 2019
At the University of Pennsylvania and in her post-doctoral studies at Stanford University, Alexis Howerton zeroed in on ways the body responds to stress, sleuthing out compounds that could tap into pathways that could be exploited.

Read More +

 

Alexis Howerton On Starting Up From New Science

02 August 2018
Source: Life Science Leader
By Wayne Koberstein, Executive Editor, Life Science Leader magazine

It is not often I meet my interview subject in the elevator on the way to our meeting room. By the time we get to the right floor, Alexis Howerton, the founding CEO of Spruce Biosciences, has recognized me from a photo and introduced herself, and we have already started the conversation. Our meeting was set only a day or so before we both attended this industry event, and I come knowing next to nothing about Spruce or its lead drug candidate, SPR001, now in midstage development for treating congenital adrenal hyperplasia (CAH).

Read More +

 

Rare Disease Report: Spruce Launches CAH Natural History Study

01 March 2018
Yesterday, in observance of Rare Disease Day, Spruce Biosciences announced the launch of the CAH Natural History Study, an initiative to advance knowledge and awareness of congenital adrenal hyperplasia (CAH).

Read More +

 

Rare Daily by Global Genes: Spruce Begins Natural History Study of Rare Endocrine Disorder CAH

28 February 2018
Spruce Biosciences said it has launched a natural history study of congenital adrenal hyperplasia, or CAH, a rare endocrine disorder caused by genetic mutations resulting in the inability to produce the critical stress hormone cortisol.

Read More +

 

Spruce Biosciences Receives FDA Orphan Drug Designation for SPR001 for the Treatment of Congenital Adrenal Hyperplasia

04 December 2017
Clinical-stage biotech granted orphan drug designation for the treatment of CAH, a rare endocrine disease.

Read More +

 

Spruce Receives Orphan Drug Designation for Treatment of Endocrine Disease

04 December 2017
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SPR001, a novel therapy being developed by Spruce Biosciences for the potential treatment of congenital adrenal hyperplasia (CAH).

Read More +

 

Rare Endocrine Play Spruce Emerges From Stealth

12 October 2017
Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding and said it has begun enrolling patients in a U.S. Phase…

Read More +

 

Rare Endocrine Play Spruce Emerges From Stealth And Announces $20m Series A

13 October 2017
Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding and said it has begun enrolling patients in a U.S. Phase…

Read More +

 

Rare Endocrine Play Spruce Emerges From Stealth And Announces $20m Series A

13 October 2017
Spruce Biosciences Inc. (San Francisco, Calif.) revealed a $20 million series A round of funding and said it has begun enrolling patients in a U.S. Phase…

Read More +

 

Sprucely Debut

13 October 2017
Why spruce believes $20 million series a could take it to pivotal testing

Read More +

 

‘Sprucing’ up the place: $20M series A takes lead asset into phase II in CAH

13 October 2017
Spruce Biosciences Inc. landed a $20 million series A last year but kept the financing under wraps, waiting for its only asset, SPR-001, to achieve its first clinical milestone. With a phase II study now testing the small molecule in adults with congenital adrenal hyperplasia (CAH), the San Francisco-based company opted to shed a bit of light on its strategy.

Read More +

 

Up and down the ladder: The latest comings and goings

13 October 2017

Read More +

 

Spruce Biosciences Grabs $20 Million to Tackle Genetic Disease

12 October 2017
Company focusing on rare endocrine conditions testing drug in mid-stage clinical studies

Read More +

 

Finance Watch: J&J Notes JLabs Incubators’ Success Stories To Date

13 October 2017
Life science firms in J&J’s JLabs incubators have raised $9.4bn to date from deals and financings, including five IPOs. Also, October brings a wide range of new equity and VC financings.

Read More +

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. We are leveraging our extensive expertise in endocrinology and orphan drug development to meet the significant unmet need of patients suffering from these diseases. We are committed to transforming the quality of life for patients who have been underserved by scientific innovation.